Evotec (NASDAQ:EVO) Trading Up 3.8%

Evotec SE (NASDAQ:EVO) shares traded up 3.8% on Friday . The stock traded as high as $3.31 and last traded at $3.31. 5,585 shares were traded during mid-day trading, a decline of 95% from the average session volume of 110,310 shares. The stock had previously closed at $3.19.

Analyst Upgrades and Downgrades

A number of equities analysts recently issued reports on the stock. HC Wainwright dropped their target price on shares of Evotec from $11.00 to $8.00 and set a “buy” rating on the stock in a research report on Thursday. Deutsche Bank Aktiengesellschaft lowered shares of Evotec from a “hold” rating to a “sell” rating in a research report on Thursday, August 8th. Finally, Morgan Stanley downgraded Evotec from an “overweight” rating to an “equal weight” rating and decreased their target price for the stock from $15.00 to $6.00 in a research report on Monday, July 29th.

Evotec Stock Up 1.6 %

The company has a debt-to-equity ratio of 0.43, a current ratio of 1.86 and a quick ratio of 1.79. The company has a 50-day simple moving average of $4.50 and a 200-day simple moving average of $5.89.

Institutional Trading of Evotec

A number of institutional investors and hedge funds have recently modified their holdings of the stock. Quadrant Capital Group LLC bought a new position in shares of Evotec during the fourth quarter worth $25,000. Vanguard Personalized Indexing Management LLC bought a new position in shares of Evotec during the 2nd quarter valued at about $87,000. Cetera Advisors LLC acquired a new position in shares of Evotec in the 1st quarter valued at approximately $188,000. Optiver Holding B.V. lifted its stake in Evotec by 643.1% in the fourth quarter. Optiver Holding B.V. now owns 80,810 shares of the company’s stock valued at $945,000 after buying an additional 69,936 shares in the last quarter. Finally, DCF Advisers LLC boosted its stake in Evotec by 140.5% in the 2nd quarter. DCF Advisers LLC now owns 114,953 shares of the company’s stock worth $552,000 after purchasing an additional 67,156 shares during the period. 5.81% of the stock is owned by institutional investors.

About Evotec

Evotec SE operates as drug discovery and development partner for the pharmaceutical and biotechnology industry worldwide. The company is developing pharmaceutical products in various therapeutic areas, such as autoimmune diseases, cancer, CNS diseases, diabetes, fibrosis, immunology, infectious diseases, kidney diseases, liver diseases, pain and inflammation, rare diseases, respiratory diseases, tuberculosis, and women's health.